NCT00266227View on ClinicalTrials.gov

A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate

PHASE3CompletedINTERVENTIONAL

Enrollment

559

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

October 31, 2007

Conditions

Rheumatoid Arthritis

Interventions

DRUG

placebo

Intravenous repeating dose

DRUG

rituximab

Intravenous repeating dose

DRUG

methotrexate

Oral or parenteral repeating dose

DRUG

folate

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY